Biotech News

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

Coherus BioSciences, Inc. (CHRS)Coherus BioSciences, Inc.2026-08-17 21:33 ESTCompany update

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS)

Coherus BioSciences, Inc.

Immuno-Oncology Portfolio Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI. Casdozokitug Casdozokitug is an anti-IL-27 antibody being studied...

Recent company news

CHRSCoherus BioSciences, Inc.2026-08-17 21:33 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

Stock data

Close: 1.15 USD
Market cap: 234.46M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights

Related news

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology to Report Second Quarter Financial Results

Bristol Myers Squibb Announces Dividend

Coherus BioSciences, Inc.

Recent company news